Skip to content

Ultrasound visualization of minimally invasive treatment of piriformis syndrome

Clinical study of ultrasound-guided piriformis trigger point injection inactivation combined with fascial hydrodissection in the treatment of piriformis syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062732
Enrollment
Unknown
Registered
2022-08-16
Start date
2022-08-11
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myofascial pain syndrome

Interventions

therapy group:Ultrasound-guided piriformis trigger point injection inactivation combined with fascial hydrolysis
control group:Ultrasound-guided inactivation of piriformis trigger point injection

Sponsors

Zhejiang Rongjun Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the above diagnostic criteria; 2. Conservative treatment failed for 3 months; 3. MRI or ultrasonography showed piriformis syndrome; 4. Patients who were unwilling to undergo surgical treatment; 5. Voluntarily join the research of this subject and can cooperate with follow-up review; 6. All agree to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined with hip trauma deformity, sacroiliitis, gynecological inflammation and other diseases with similar PS complaints; 2. Known allergic to experimental drugs; 3. Severe heart, liver, and kidney damage; 4. Currently taking glucocorticoids; 5. Patients taking vitamin B12 drugs, including cyanocobalamin, hydroxocobalamin, adenosylcobalamin and domestically produced methylcobalamin; 6. Women of childbearing age who take measures; 7. Those who combine other conservative treatment methods at the same time; 8. Local infection; 9. complicated with diabetes; 10. MRI or ultrasound showed space-occupying lesions in the hip and buttocks; 11, patients with mental disorders, unable to cooperate with the treatment.

Design outcomes

Primary

MeasureTime frame
( visual analog scale, VAS);Lee's hip function score;

Countries

China

Contacts

Public ContactMingmin Xu

Zhejiang Rongjun Hospital

mingminxu@126.com+86 13511300148

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026